Across 114 CTIS dermatology Phase III trials authorized in 2024–2026, EU site activity is highly concentrated in a repeat Spanish dermatology network. Hospital Universitario La Paz was the leading site by participation records with 18 appearances, followed by Hospital Universitario y Politécnico La Fe with 14 and Hospital Clínic de Barcelona with 12. The top 10 recurring sites accounted for 86 of 502 identified site participation records, equal to 17.1% of all listed site records.
The leading 10 sites generated 86 of 502 identified site participation records, or 17.1% of all listed site records. Spanish sites dominate the ranking: 9 of the top 10 sites are in Spain, with one Polish site, Provita Sp. z o.o., entering the top group.
Dermatology Phase III execution appears to rely heavily on repeat high-volume Spanish sites, especially Madrid, Barcelona, Valencia, Granada, and Córdoba. This suggests that sponsors returning to Europe for late-stage dermatology studies may repeatedly select the same experienced investigator networks.
The top 3 sites contributed 44 of the 86 top-10 site participation records, or 51.2% of the top-10 total. Hospital Universitario La Paz alone contributed 18 of 86 top-10 records, equal to 20.9% of the top-ranked network.
The top-site network is not only Spanish-heavy but also concentrated around a small number of repeatedly selected centers. Operationally, this creates advantages for speed and investigator familiarity, but it may also increase competition for the same patient pools across parallel dermatology programs.
In the largest 2026 Phase III dermatology allocation record, Poland carried 458 participants across 30 sites, Germany carried 227 participants across 29 sites, and Czechia carried 165 participants across 13 sites. Together, these three countries accounted for 850 of 1,289 allocated participants, or 65.9%.
| Country | Participants | Sites | Participant share |
|---|---|---|---|
| Poland | 458 | 30 | 35.5% |
| Germany | 227 | 29 | 17.6% |
| Czechia | 165 | 13 | 12.8% |
| Spain | 93 | 10 | 7.2% |
| Hungary | 89 | 9 | 6.9% |
| Romania | 81 | 11 | 6.3% |
Poland and Germany appear as major country-level capacity engines for large Phase III dermatology allocations, while Spain contributes a smaller allocation share in this 2026 record but dominates the recurring top-site list.
The 2026 data show a large moderate-to-severe plaque psoriasis allocation with 1,289 total participants across 128 sites. In 2025, indolent systemic mastocytosis with skin involvement appears as a smaller late-stage dermatology-immunology signal, including a 66-participant Polish allocation across 3 sites.
Plaque psoriasis remains a major late-stage capacity driver because it supports broad country allocation and large site footprints. Smaller immune-dermatology indications appear more concentrated and may depend on specialist centers rather than broad national site networks.
A site participation record means one appearance of a named site in a trial geography file. It is a frequency measure of how often a site appears across trials, not a direct measure of the number of patients enrolled at that site. Country participant allocations are reported from CTIS country-level participant fields.